KOREA WHO
-
-
-
Chairman of Komipharm
Yang Kyung-hoon
With over 50 years in the animal vaccine industry, he is now focusing his efforts on commercializing the new drug, Cominox.
-
Last Updated on Nov 13, 2024
-
Chairman of Komipharm
Life Summary
Yang Kyung-hoon is the Co-CEO and Chairman of Komipharm.
He manages the company together with Co-CEO Moon Sung-chul, with Yang overseeing the human pharmaceuticals division and Moon handling the animal health business.
Yang was born on August 1, 1953, in Incheon.
His former name was Yang Yong-jin, and he legally changed his name in 2022.
He graduated from Ganghwa High School in Incheon and then earned a law degree from Kukje University. He later pursued a Master’s degree in Business Administration from Inha University Graduate School.
In 1988, he became CEO of the Korea Microbial Research Institute, the predecessor of Komipharm. He was appointed Chairman and CEO of Komipharm in 2004.
Yang expanded Komipharm's business from manufacturing and selling animal health products to include human pharmaceuticals.
Komipharm is conducting international clinical trials for its anticancer drug Kominox (PAX-1) as part of its product development efforts.
In 2024, the company entered the home environment improvement sector by launching a new business manufacturing and selling low-power air conditioners without external units.
Yang plans to use the revenue generated from this new venture to fund the late-stage clinical trials of Kominox, aiming to bring the product to market.
#YangKyunghoon #Komipharm #CoCEO #humanpharmaceuticals #animalhealth #anticancerdrug #Kominox #businessdiversification #clinicaltrials #newbusiness
He manages the company together with Co-CEO Moon Sung-chul, with Yang overseeing the human pharmaceuticals division and Moon handling the animal health business.
Yang was born on August 1, 1953, in Incheon.
His former name was Yang Yong-jin, and he legally changed his name in 2022.
He graduated from Ganghwa High School in Incheon and then earned a law degree from Kukje University. He later pursued a Master’s degree in Business Administration from Inha University Graduate School.
In 1988, he became CEO of the Korea Microbial Research Institute, the predecessor of Komipharm. He was appointed Chairman and CEO of Komipharm in 2004.
Yang expanded Komipharm's business from manufacturing and selling animal health products to include human pharmaceuticals.
Komipharm is conducting international clinical trials for its anticancer drug Kominox (PAX-1) as part of its product development efforts.
In 2024, the company entered the home environment improvement sector by launching a new business manufacturing and selling low-power air conditioners without external units.
Yang plans to use the revenue generated from this new venture to fund the late-stage clinical trials of Kominox, aiming to bring the product to market.
#YangKyunghoon #Komipharm #CoCEO #humanpharmaceuticals #animalhealth #anticancerdrug #Kominox #businessdiversification #clinicaltrials #newbusiness